10	9	00	7	9	U	4	ω	2	Ľ	
BRS	BRS	BRS	BRS	BRS	BRS	BRS	BRS	BRS	BRS	Туре
L10	L9	L8	L7	16	L5	L4	L3	L2	L1	# #
ω	ω	27	24	74	356	2156	8719	419	768	Hits
((((aberrant adj splicing) same cell) same disease) or (cystic adj fibrosis)) same (((alternative adj splicing adj factor) or asf) or (SR adj protein) or ((heterogeneous adj nuclear adj ribonucleoprotein adj al) or hbrnpal) or (E4-ORF3 or E4-ORF6))	(cystic adj fibrosis) same ((alternative adj splicing adj factor) or asf)	E4-ORF3 or E4-ORF6	(heterogeneous adj nuclear adj ribonucleoprotein adj a1) or hbrnpal	SR adj protein	((aberrant adj splicing) same cell) same disease	(alternative adj splicing adj factor) or asf	cystic adj fibrosis	(aberrant adj splicing) same cell	aberrant adj splicing	Search Text
USPAT; US-PGPUB; EPO; JPO; DERWENT	USPAT; US-PGPUB; EPO; JPO; DERWENT	USPAT; US-PGPUB; EPO; JPO; DERWENT	USPAT; US-PGPUB; EPO; JPO; DERWENT	USPAT; US-PGPUB; EPO; JPO; DERWENI	USPAT; US-PGPUB; EPO; JPO; DERWENT	USPAT; US-PGPUB; EPO; JPO; DERWENT	USPAT; US-PGPUB; EPO; JPO; DERWENT	USPAT; US-PGPUB; EPO; JPO; DERWENT	USPAT; US-PGPUB; EPO; JPO; DERWENT	DBs
2003/05/1	2003/05/1 2 1 5:19	2003/05/1 2 15:19	2003/05/1 2 15:18	2003/05/1 2 15:1 8	2003/05/1 2 15:18	2003/05/1 2 15:17	2003/05/1 2 15:17	2003/05/1 2 15:17	2003/05/1 2 15:17	Time Stamp
										Comm
		_	-				_	-		Error Defin ition
0	0	0	0	0	0	0	0	0	0	R R R R R

0			2003/05/1	USPAT; US-PGPUB; EPO; JPO; DERWENT	kerem adj batsheva.in.	Н	L12	12 BRS	12
0			2003/05/1	:	alternative adj splicing adj factor	11	L11 11	11 BRS	11
R C C E	Error Defin ition	Comm	Time Stamp	DBs	Search Text	Hits	Ľ#	Type L # Hits	

FILE 'HOME' ENTERED AT 15:27:34 ON 12 MAY 2003 => file medline caplus biosis embase scisearch agricola COST IN U.S. DOLLARS SINCE FILE TOTAL SESSION ENTRY 0.21 0.21 FULL ESTIMATED COST FILE 'MEDLINE' ENTERED AT 15:27:56 ON 12 MAY 2003 FILE 'CAPLUS' ENTERED AT 15:27:56 ON 12 MAY 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS) FILE 'BIOSIS' ENTERED AT 15:27:56 ON 12 MAY 2003 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R) FILE 'EMBASE' ENTERED AT 15:27:56 ON 12 MAY 2003 COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved. FILE 'SCISEARCH' ENTERED AT 15:27:56 ON 12 MAY 2003 COPYRIGHT 2003 THOMSON ISI FILE 'AGRICOLA' ENTERED AT 15:27:56 ON 12 MAY 2003 => s alternative splicing factor 204 ALTERNATIVE SPLICING FACTOR => s aberrant splicing 1787 ABERRANT SPLICING L2 => s 12 (p) cell 668 L2 (P) CELL L3 => s (cystic fibrosis) or (spinal muscular atrophy) 99976 (CYSTIC FIBROSIS) OR (SPINAL MUSCULAR ATROPHY) => s disease (p) 13 128 DISEASE (P) L3 => s 12 (p) (13 or 14) 683 L2 (P) (L3 OR L4) L6 => s disease (p) 12 382 DISEASE (P) L2 => s (16 or 17) (p) 11 0 (L6 OR L7) (P) L1 => s sr protein 2807 SR PROTEIN => s heterogeneous nuclear ribonucleoprotein a1 T₁10 323 HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1 => s e4-orf3 or e4-orf6 L11 197 E4-ORF3 OR E4-ORF6 => s 19 or 110 or 111 3311 L9 OR L10 OR L11 L12 => d his (FILE 'HOME' ENTERED AT 15:27:34 ON 12 MAY 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT

15:27:56 ON 12 MAY 2003

204 S ALTERNATIVE SPLICING FACTOR

1787 S ABERRANT SPLICING

668 S L2 (P) CELL

L1

L2

L3

```
OR (SPINAL MUSCULAR ATROPHY)
          99976 S (CYSTIC FIBROSIA
            128 S DISEASE (P) L3
L5
            683 S L2 (P) (L3 OR L4)
L6
            382 S DISEASE (P) L2
L7
              0 S (L6 OR L7 ) (P) L1
L8
           2807 S SR PROTEIN
L9
            323 S HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1
L10
            197 S E4-ORF3 OR E4-ORF6
L11
           3311 S L9 OR L10 OR L11
L12
=> s (16 or 17) (p) 112
             5 (L6 OR L7) (P) L12
L13
=> duplicate remove 113
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L13
              1 DUPLICATE REMOVE L13 (4 DUPLICATES REMOVED)
=> d 114 1 ibib abs
                                                        DUPLICATE 1
                       MEDLINE
L14 ANSWER 1 OF 1
ACCESSION NUMBER:
                    2001229125
                                   MEDLINE
                    21181834 PubMed ID: 11285240
DOCUMENT NUMBER:
                    Nuclear factor TDP-43 and SR proteins promote in vitro and
TITLE:
                    in vivo CFTR exon 9 skipping.
                    Buratti E; Dork T; Zuccato E; Pagani F; Romano M; Baralle F
AUTHOR:
                    International Centre for Genetic Engineering and
CORPORATE SOURCE:
                    Biotechnology (ICGEB), Padriciano 99, 34012 Trieste, Italy.
                    EMBO JOURNAL, (2001 Apr 2) 20 (7) 1774-84.
SOURCE:
                    Journal code: 8208664. ISSN: 0261-4189.
                    England: United Kingdom
PUB. COUNTRY:
                    Journal; Article; (JOURNAL ARTICLE)
DOCUMENT TYPE:
                    English
LANGUAGE:
                    Priority Journals
FILE SEGMENT:
                    200106
ENTRY MONTH:
                    Entered STN: 20010611
ENTRY DATE:
                    Last Updated on STN: 20010611
                    Entered Medline: 20010607
     Alternative splicing of human ***cystic***
                                                      ***fibrosis***
     transmembrane conductance regulator (CFTR) exon 9 is regulated by a
     combination of cis-acting elements distributed through the exon and both
     flanking introns (IVS8 and IVS9). Several studies have identified in the
     IVS8 intron 3' splice site a regulatory element that is composed of a
     polymorphic (TG)m(T)n repeated sequence. At present, no cellular factors
     have been identified that recognize this element. We have identified
     TDP-43, a nuclear protein not previously described to bill kink, as the
     factor binding specifically to the (TG)m sequence. Transient TDP-43
     overexpression in Hep3B ***cells*** results in an increase in exon 9
     skipping. This effect is more pronounced with concomitant overexpression
                     ***proteins*** . Antisense inhibition of endogenous
          ***SR***
     TDP-43 expression results in increased inclusion of exon 9, providing a
     new therapeutic target to correct ***aberrant***
                                                             ***splicing***
     exon 9 in CF patients. The clinical and biological relevance of this
     finding in vivo is demonstrated by our characterization of a CF patient
     carrying a TG10T9(DeltaF508)/TG13T3(wt) genotype leading to a
        ***disease*** -causing high proportion of exon 9 skipping.
=> d his
      (FILE 'HOME' ENTERED AT 15:27:34 ON 12 MAY 2003)
     FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
     15:27:56 ON 12 MAY 2003
            204 S ALTERNATIVE SPLICING FACTOR
L1
            1787 S ABERRANT SPLICING
L2
1.3
            668 S L2 (P) CELL
          99976 S (CYSTIC FIBROSIS) OR (SPINAL MUSCULAR ATROPHY)
L4
            128 S DISEASE (P) L3
L5
```

683 S L2 (P) (L3 OR L4)

1.6

L7	382	S DISEASE (P) L2	
L8	0	S (L6 OR L7) (P)	
L9	2807	S SR PROTEIN	
L10	323	S HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1	
L11	197	S E4-ORF3 OR E4-ORF6	
L12	3311	. S L9 OR L10 OR L11	
L13	5	S S (L6 OR L7) (P) L12	
L14	1	DUPLICATE REMOVE L13 (4 DUPLICATES REMOVED)	
=> log y			
COST IN U.	s. DOI	LLARS SINCE FILE	TOTAL
		ENTRY	SESSION
FULL ESTIMA	ATED (COST 50.16	50.37

STN INTERNATIONAL LOGOFF AT 15:34:58 ON 12 MAY 2003